Abstract
Progressive B-cell chronic lymphocytic leukemia (B-CLL) is often complicated by autoimmune hemolytic anemia (AIHA), which in some cases may be refractory to conventional therapy such as corticosteroids, rituximab and splenectomy. We report here on 5 patients (median age 66 years, range 59–69) with advanced B-CLL, all of whom developed severe transfusion-dependent AIHA resistant to conventional therapy and received subcutaneous (SC) or intravenous (IV) alemtuzumab, a humanized monoclonal antibody that targets the CD52 antigen as salvage treatment for AIHA. Alemtuzumab was well tolerated with only minor ‘first dose’ reactions. All 5 patients responded with a ⩾2.0 g/dl rise in hemoglobin (Hb) concentration, in the absence of further transfusions, after a median time of 5 weeks (range 4–7), and the mean Hb increased from 7.2 g/dl at baseline to 11.9 g/dl at end of treatment. All patients remained stable, without further AIHA episodes, after a median follow-up time of 12 months with a mean Hb of 12.5 g/dl (range 12.2–12.9). For patients with severe, refractory CLL-related AIHA, who have not previously responded to conventional therapy, alemtuzumab is an effective agent.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Diehl LF, Ketchum LH . Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998; 25: 80–97.
Mauro FR, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000; 95: 2786–2792.
Bastion Y, Coiffier B, Dumontet C, Espinouse D, Bryon PA . Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia. Ann Oncol 1992; 3: 171–172.
Juliusson G . Complications in the treatment of CLL with purine analogues. Hematol Cell Ther 1997; 39 (Suppl 1): S41–S44.
Weiss RB, Freiman J, Kweder SL, Diehl LF, Byrd JC . Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 1998; 16: 1885–1889.
Efremov DG, Ivanovski M, Siljanovski N, Pozzato G, Cevreska L, Fais F et al. Restricted immunoglobulin VH region repertoire in chronic lymphocytic leukemia patients with autoimmune hemolytic anemia. Blood 1996; 87: 3869–3876.
Kipps TJ, Carson DA . Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood 1993; 81: 2475–2487.
Robak T . Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol 2004; 72: 79–88.
Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–3561.
Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768–773.
Osterborg A, Fassas AS, Anagnostopoulos A, Dyer MJ, Catovsky D, Mellstedt H . Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 1996; 93: 151–153.
Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J Clin Oncol 1997; 15: 1567–1574.
Lundin J, Porwit-MacDonald A, Rossmann ED, Karlsson C, Edman P, Rezvany MR et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004; 18: 484–490.
Lundin J, Karlsson C, Celsing F . Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia. Med Oncol 2006; 23: 137–139.
Cheson BD, Bennet JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute – sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.
Shanafelt TD, Madueme HL, Wolf RC, Tefferi A . Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc 2003; 78: 1340–1346.
Narat S, Gandla J, Hoffbrand AV, Hughes RG, Mehta AB . Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica 2005; 90: 1273–1274.
Gupta N, Kavuru S, Patel D, Janson D, Driscoll N, Ahmed S et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 2002; 16: 2092–2095.
Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol 2001; 114: 891–898.
Cheung WW, Hwang GY, Tse E, Kwong YL . Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab. Haematologica 2006; 91: 21–22.
Marsh JC, Gordon-Smith EC . CAMPATH-1H in the treatment of autoimmune cytopenias. Cytotherapy 2001; 3: 189–195.
Schützinger C, Gaiger A, Thalhammer R, Vesely M, Fritsche-Polanz R, Schwarzinger I et al. Remission of pure red cell aplasia in T-cell receptor γδ-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab. Leukemia 2005; 19: 2005–2008.
Rodon P, Breton P, Courouble G . Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath-1H. Eur J Haematol 203; 70: 319–321.
Acknowledgements
This study was supported by grants from the Swedish Cancer Society, The Cancer Society in Stockholm and The Karolinska Institutet Foundations.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Karlsson, C., Hansson, L., Celsing, F. et al. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia 21, 511–514 (2007). https://doi.org/10.1038/sj.leu.2404512
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404512
Keywords
This article is cited by
-
A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia
Current Hematologic Malignancy Reports (2017)
-
Rituximab–cyclophosphamide–dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia
Leukemia (2011)
-
Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia
Leukemia (2009)
-
Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia
Current Hematologic Malignancy Reports (2009)
-
Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review
Wiener klinische Wochenschrift (2008)